Asset sale strategies tend to be pursued predominantly smaller drug development companies seeking to generate income from their early development pipelines. For this reason, many of our asset sales case studies are similar to those for proof-of-concept. The same principles of simple investigational design and robust analytical insight are used in this context to show value to a potential buyer.
Hypertension renin inhibitors
Improve bioavailability of lead compound by investigating microdose amounts of different congeners in the clinic
Increased lead compound bioavailability (2.6%) to >30%. Formed the basis of Speedel’s renin inhibitor series. Speedel subsequently bought by Novartis for $880MM in 2008 on the basis of this and other compounds in their development pipeline. Speedel highlighted:
Determine absolute bioavailability, and routes and rates of clearance with full quantitative metabolite profiles in urine and feces.
Company recently acquired by one of Xceleron’s European large pharma clients for $750MM US in order to obtain Phase II compound. The acquiring company appreciated the value of this data and are now discussing with Xceleron how to adopt the approach in their early clinical development programs. This drug, an androgen receptor antagonist, is now on Phase III in non-metastatic prostate cancer patients
Use a microdose investigation of two non-nucleoside reverse transcriptase inhibitors to select a lead candidate on the basis of clinical PK and metaolism
Helped to design a human microdose investigation
IDX899 was taken into Phase II by Idenix before being licensed to GSK for an upfront payment of $34MM
Determine blood-brain barrier penetration of two novel drug candidates by measuring drug CSF levels
Lead candidate drug was eventually sold to a Japanese Big Pharma in a deal worth $760MM
Xceleron is acquired by Pharmaron
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.